C. Di Muzio

发表

Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications.

R. Giacomelli, F. Ursini, P. Ruscitti, 2022, Autoimmunity reviews.

Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association

P. Ruscitti, P. Cipriani, C. Di Muzio, 2022, BioDrugs.

Assessment of health-related quality of life in patients with adult onset Still disease: Results from a multicentre cross-sectional study.

A. Iagnocco, F. Ciccia, R. Giacomelli, 2022, Medicine.

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still’s disease

A. Iagnocco, C. Montecucco, F. Atzeni, 2022, Rheumatology.

Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting

A. Alunno, F. Carubbi, V. Pavlych, 2020, Frontiers in Medicine.

Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a “real-life” study

R. Giacomelli, P. Ruscitti, P. Cipriani, 2022, Medicine.

Tofacitinib may improve insulin resistance in patients with rheumatoid arthritis and diabetes, implications for disease management and precision medicine approach.

A. Iagnocco, R. Giacomelli, P. Ruscitti, 2023, Autoimmunity reviews.

The hyper-expression of NLRP4 characterizes the occurrence of macrophage activation syndrome assessing STING pathway in adult-onset Still's disease.

R. Giacomelli, P. Ruscitti, O. Berardicurti, 2022, Clinical and experimental immunology.

Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry

A. Iagnocco, F. Masedu, B. Ogunjimi, 2023, RMD Open.

Adult-onset Still's disease with elderly onset, results from a multicentre study.

A. Iagnocco, S. Bugatti, C. Montecucco, 2021, Clinical and experimental rheumatology.

The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study

A. Iagnocco, P. Ruscitti, I. Di Cola, 2024, Arthritis research & therapy.

The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational “real-life” study

P. Ruscitti, O. Berardicurti, L. Navarini, 2023, Scientific reports.

The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort.

F. Cipollone, F. Ciccia, R. Giacomelli, 2023, Clinical and experimental rheumatology.